The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma
The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma
复制标题
DOI：
10.1046/j.1464-410x.1997.03399.x
复制
发表时间：
1997-02-01
期刊：
影响因子：
--
通讯作者：
Hamdy, FC
中科院分区：
文献类型：
--
作者：
Byrne, RL;Horne, CHW;Hamdy, FC
目的探讨waf-1（一种由p53调控的细胞周期蛋白依赖性激酶抑制剂）、p53、bcl-2的表达与前列腺癌肿瘤进展的关系。患者和方法：选取40例经组织学证实的前列腺癌患者（平均年龄73岁，55-88岁），通过活检或前列腺切除术获得前列腺组织样本，采用免疫组化染色检测三种基因产物的表达，以及与患者分期、分级、疾病进展和生存相关的表达。结果18例waf-1阳性患者中15例，12例bcl-2阳性患者中10例，19例p53阳性患者中17例发生肿瘤进展，19例p53阳性患者中15例发生肿瘤低分化，21例p53阴性患者中11例发生肿瘤低分化(P
Objective To determine the associations between the expression of waf-1 (a cyclin-dependent kinase inhibitor regulated by p53), p53, bcl-2 and tumour progression in prostate cancer.Patients and methods Samples of prostatic tissue were obtained by biopsy or at prostatectomy from 40 men (mean age 73 years, range 55-88) with histologically confirmed prostate cancer, examined using immunohistochemical staining for the three gene products, and the expression related to the stage, grade, disease progression and survival of the patients.Results Fifteen of 18 patients whose tumours were positive for waf-1, 10 of 12 positive for bcl-2 and 17 of 19 positive for p53 had disease progression, Fifteen of 19 patients positive for p53 had poorly differentiated tumours compared with 11 of 21 negative for p53 (P